Megestrol acetate versus aminoglutethimide for metastatic breast cancer

Breast Cancer Res Treat. 1989 Nov;14(2):201-6. doi: 10.1007/BF01810736.

Abstract

In this prospective, randomized study the clinical response and toxicity of megestrol acetate (MA) and aminoglutethimide (AG) as second-line treatment in patients with metastatic breast cancer was compared. 176 patients were included, and 150 received treatment greater than 8 weeks and are evaluable for treatment response. The two groups did not differ with regard to prognostic factors. Response rate for the AG and MA groups were 34% and 31% respectively, with duration of response of 13.1 and 13.0 months. Stable disease was obtained in 33% and 35% respectively. No difference was observed in survival. Side effects occurred more frequently in the AG group (42%) than in the MA group (18%).

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aminoglutethimide / adverse effects
  • Aminoglutethimide / therapeutic use*
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / mortality
  • Bone Neoplasms / secondary*
  • Breast Neoplasms / drug therapy*
  • Female
  • Follow-Up Studies
  • Humans
  • Megestrol / adverse effects
  • Megestrol / therapeutic use*
  • Middle Aged
  • Multicenter Studies as Topic
  • Neoplasm Metastasis
  • Neoplasm Recurrence, Local / drug therapy
  • Prospective Studies
  • Randomized Controlled Trials as Topic
  • Receptors, Estrogen / analysis
  • Receptors, Progesterone / analysis
  • Tamoxifen / therapeutic use

Substances

  • Receptors, Estrogen
  • Receptors, Progesterone
  • Tamoxifen
  • Aminoglutethimide
  • Megestrol